Technical420 Site Search

Earlier this month, GW Pharmaceuticals (GWPH) reported positive results from the first Phase 3 Clinical study for its Epidiolex product and this has served as a catalyst for several publicly traded cannabis companies.This rally can be described as nothing short of a volatile explosion upward as some of the stocks…

After GW Pharmaceuticals (GWPH) reported overwhelmingly positive results from its first Phase 3 study on its Epidiolex product, several cannabis stocks rallied and we think this is just the start of something big.Our rationale is based off of GWPH proving that cannabis should not be labeled as Schedule I substance.…

GW Pharmaceuticals plc (GWPH) just changed the game…Shares of GW Pharmaceuticals plc (GWPH) are up over 100% after announcing positive results for the first Phase 3 Clinical study for its Epidiolex product (for the treatment of Dravet syndrome).In this study, Epidiolex achieved the primary endpoint of a significant reduction in…

Numbers don’t lie.Or do they?As an analyst I know they don’t lie, but they don’t always tell the whole story.Today’s tale is a perfect example.GW Pharmaceuticals (GWPH) and Insys Therapeutics, Inc. (INSY) recently reported financial results and the companies have seen opposite reactions from the market.Yesterday, INSY fell almost 3%…

GW Pharmaceuticals plc (GWPH) is a pharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United…

Although it looks like shares of GW Pharmaceuticals plc (GWPH) recently found a bottom in the high $70s, we expect to see further weakness after the company reported poor top-line results from its Phase 3 trials for its Sativex product.Today, GWPH and Otsuka Pharmaceutical Development & Commercialization, Inc. reported top-line…

One of the sectors that have been hit the hardest during the last three months is the biotech sector and many investors are wondering if it is time to buy. Although recent weakness has made many biotech investments look attractive, we remain on the sidelines with many blue chip investments…

The National Cancer Institute (NCI) updated its website to include various studies revealing how cannabis may inhibit tumor growth by killing cells, blocking cell growth, and blocking the development of blood vessels that tumors need to grow. The institute released the following statement after updating its website:“A laboratory study of…

What happens when you combine a hot biotech initial public offering (IPO) market with a NASDAQ traded cannabis stock focused on treatments that have a multi-billion dollar Total Addressable Market (TAM)?  Just take a look at Zynerba Pharmaceuticals (ZYNE).On August 5th, ZYNE conducted its IPO on the NASDAQ exchange and…

GW Pharmaceuticals (GWPH) and Insys Therapeutics, Inc. (INSY) reported third-quarter financial results this morning and the companies have seen opposite reactions from the market.Shares of GWPH rallied 4% off of the open, while INSY plummeted 11%. INSY has rallied off of its lows but we see further weakness ahead. Let’s highlight the results…